e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

187.40 +1.40 (+0.75%)

Streaming Delayed Price Updated: 2:31 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

57 58 Next >

Biogen (BIIB) Q2 2023 Earnings Call Transcript ↗

July 25, 2023

BIIB earnings call for the period ending June 30, 2023.

Via The Motley Fool

Ron DeSantis Escapes Car Accident Unhurt En Route To Campaign Event, TikTok Takes On Twitter, Analysts Expect Nvidia's AI Revenues To Reach $300B In Five Years: Today's Top Stories ↗

July 25, 2023

The Hill Ron DeSantis Escapes Car Accident Unhurt En Route To Campaign Event

Via Benzinga

WMT Stock Alert: Is Walmart Really Worth $210? ↗

July 25, 2023

Walmart (WMT) stock is in the news Tuesday as investors react to the latest coverage from Piper Sandler analyst Edward Yruma.

Via InvestorPlace

MBLY Stock Alert: Morgan Stanley Restarts Mobileye Coverage ↗

July 25, 2023

Mobileye (MBLY) stock is on the move Tuesday after Morgan Stanley analyst Adam Jonas renewed coverage of the company's shares.

Via InvestorPlace

Biogen Inc. Tops Q2 Earnings And Revenue Estimates ↗

July 25, 2023

Biogen Inc. came out with quarterly earnings of $4.02 per share.

Via Talk Markets

Better Big Biotech Buy: Vertex vs. Biogen ↗

July 24, 2023

These companies have a track record of billion-dollar earnings.

Via The Motley Fool

Biogen Earnings Preview ↗

July 24, 2023

Via Benzinga

Biogen Unusual Options Activity ↗

July 21, 2023

Via Benzinga

Biogen Layoffs 2023: What to Know About the Latest BIIB Job Cuts ↗

July 25, 2023

Biogen (BIIB) layoffs are on the way as the company seeks further profits with its upcoming Alzheimer's disease drug launch.

Via InvestorPlace

Biogen Q2 Earnings Tops Expectations, Shift Resources To Higher Value Area(s), Layoff 1K Staff ↗

July 25, 2023

Biogen Inc (NASDAQ: BIIB) posted Q2 FY23 sales of $2.46 billion, beating the con

Via Benzinga

Nasdaq Futures Rise Ahead Of Microsoft, Alphabet Earnings: Analyst Warns Of Volatility From Fed's Message 'Crafting' ↗

July 25, 2023

Via Benzinga

All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings ↗

July 24, 2023

Analysts expect Biogen to report a a decline in both profits and sales in Q2.

Via Investor's Business Daily

Goldman Sachs, Charles Schwab And This Healthcare Stock On CNBC's 'Final Trades' ↗

July 21, 2023

On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Biogen Inc.

Via Benzinga

(BIIB) - Analyzing Biogen's Short Interest ↗

July 20, 2023

Via Benzinga

Is Biogen Stock a Buy Now? ↗

July 19, 2023

The biotech hasn't been the best investment recently.

Via The Motley Fool

Should You Buy the Dip With Biogen Stock Right Now? ↗

July 17, 2023

It's expected to grow, but things might not work out precisely as planned.

Via The Motley Fool

Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023

July 19, 2023

From Biogen Inc.

Via GlobeNewswire

Acumen Soars on Alzheimer's Study...Street Sees It Doubling

July 19, 2023

Will the $11.00 level be a double-top ceiling…or can Acumen Pharmaceuticals build momentum and climb towards its $25.00 IPO price?

Via MarketBeat

Topics Initial Public Offering

These 2 Numbers Should Scare Every Biogen Shareholder ↗

July 16, 2023

There are a couple of pieces of evidence that Biogen's long-term strategy isn't working.

Via The Motley Fool

7 Stocks That AI Says Will Make You a Millionaire by 2025 ↗

July 13, 2023

These seven millionaire-maker stocks are changing hands at deeply undervalued levels. As their growth re-accelerates, so will your portfolio.

Via InvestorPlace

P/E Ratio Insights for Biogen ↗

July 12, 2023

Via Benzinga

Biogen Just Reached a Big Milestone. Why Isn't the Stock Rising? ↗

July 09, 2023

Biogen shares are little changed year to date.

Via The Motley Fool

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $4,900 Today ↗

July 07, 2023

Via Benzinga

Why Isn't Biogen Stock Soaring After This Major FDA Approval? ↗

July 13, 2023

Is the stock a good contrarian buy?

Via The Motley Fool

Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi

July 10, 2023

Biogen's shares decline after approval of Alzheimer's treatment Leqembi, which modestly slows cognitive decline. Analysts see hurdles to the rollout.

Via MarketBeat

Mixed Jobs Data; Fed Governors Want More Interest Rate Hikes; US, China Spat Rattles Semiconductor Sector: The Week In The Markets ↗

July 07, 2023

Via Benzinga

Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts ↗

July 07, 2023

The FDA approved a supplemental marketing application for Biogen Inc (NASDAQ: BIIB)-Eisai Co Ltd (OTC: ESALY) supporting the traditional approval of Leqembi (lecanemab-irmb), making it the first and...

Via Benzinga

FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline ↗

July 07, 2023

The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval.

Via Benzinga

Stock Market Rally Pulls Back As Yields Jump; Tesla, Meta In Focus: Weekly Review ↗

July 07, 2023

Automakers rallied on sales while Meta's Threads had a big launch.

Via Investor's Business Daily

FSLR Stock Alert: The $1 Billion Reason First Solar Is Up Today ↗

July 07, 2023

First Solar (FSLR) stock is rising higher on Friday after the solar energy company announced a $1 billion revolving credit facility.

Via InvestorPlace

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

57 58 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy